Navigation Links
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Date:12/10/2010

SAN ANTONIO Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.

<
'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
2. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. First X-ray lasers early success brings approval for next-phase facility
6. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
7. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
8. First phase of pan-tropical forest mapping debuting at COP15
9. NIH funds new phase of high school-university research partnership
10. Scientists seek new emphases in Arctic climate change research
11. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... hydrogen sulfide in order to properly multiply and form ... Center for Craniofacial Molecular Biology at the Herman Ostrow ... principal investigator on the project, said the presence of ... of calcium ions. The essential ions activate a chain ... creation of new bone tissue, and keeps the breakdown ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... "dietary fibre". But what is dietary fibre and how do ... Structural Biology Laboratory, in collaboration with groups in Canada, the ... bacteria metabolise the complex dietary carbohydrates found in fruits and ... are about ten times more bacterial cells in the average ...
... alien world of aquatic micro-organisms just got new residents: ... has developed a class of tiny bio-hybrid machines that ... traverse the viscous fluids of biological environments on their ... Gutgsell Professor of mechanical science and engineering, the team ...
... researchers from the University of Nebraska-Lincoln, while using a ... Ice Shelf, unexpectedly discovered a new species of small ... tentacles protruding into frigid water like flowers from a ... it was really an amazing find," said Marymegan Daly, ...
Cached Biology News:York scientists investigate the fiber of our being 2Tiny swimming bio-bots boldly go where no bot has swum before 2New sea anemone species discovered in Antarctica 2New sea anemone species discovered in Antarctica 3New sea anemone species discovered in Antarctica 4
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... N.J., Jan. 28 Arno Therapeutics, Inc., a,privately ... entered into,worldwide, exclusive license agreements with The Ohio ... novel, orally available,targeted therapies for cancer., Pursuant ... to several,small molecules for the treatment of cancer, ...
... Paper Provides Rationale for Continued Development of CNDO103 as ... ... Coronado Biosciences Inc. today,announced the publication of data demonstrating that the ... while,demonstrating less toxicity than Gossypol in vivo in mice., Published ...
... Jan. 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced it has completed ... to discuss the upcoming IND,submission for ARH460-16-2, its ... anti-cancer antibody targeting a novel epitope of CD44,found ...
Cached Biology Technology:Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 3Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 3Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 2Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 3
... ejector is a unique product that facilitates ... their holder. Linkage: This CLS number is ... match Cornings product number. If showing no ... Sigma-Aldrich number (Z71,314-7) or contact customer service ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
... The Staccato Series of systems provide ... drug discovery , genomics, proteomics and drug ... three base configurations; Mini Workstation Series, Application ... Sciclone ELISA Station is a remarkably compact ...
Biology Products: